ChiCTR2300069252 版本V1.0 版本创建时间2023/03/10 15:04:26 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300069252 

最近更新日期:

Date of Last Refreshed on:

2023-03-10 15:04:20 

注册时间:

Date of Registration:

2023-03-10 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

共聚焦显微镜观察2型糖尿病患者睑板腺形态与干眼的相关性研究

Public title:

Correlation between morphology of Meibomian Gland and changes of corneal nerve in patients with type 2 diabetes Mellitus by confocal microscopy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

共聚焦显微镜观察2型糖尿病患者睑板腺形态与干眼的相关性研究

Scientific title:

Correlation between morphology of Meibomian Gland and changes of corneal nerve in patients with type 2 diabetes Mellitus by confocal microscopy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

孔倩倩 

研究负责人:

孙大鹏 

Applicant:

Qianqian Kong 

Study leader:

Sunda Peng 

申请注册联系人电话:

Applicant telephone:

+86 15554246325

研究负责人电话:

Study leader's telephone:

+86 13963903493

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1144309423@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1144309423@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省青岛市市南区燕儿岛路5号

研究负责人通讯地址:

山东省青岛市市南区燕儿岛路5号

Applicant address:

5 Yan'erdao Road, Shinan District, Qingdao, Shandong, China

Study leader's address:

5 Yan'erdao Road, Shinan District, Qingdao, Shandong, China

申请注册联系人邮政编码:

Applicant postcode:

266071

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山东第一医科大学(山东省医学科学院)山东省眼科研究所 山东省眼科学重点实验室省部共建国家重点实验室培育基地 青岛眼科医院

Applicant's institution:

Qingdao Eye Hospital, Shandong Eye Institute, Shandong First Medical University & Shandong Academy of Medical Science

研究负责人所在单位:

山东第一医科大学(山东省医学科学院)山东省眼科研究所 山东省眼科学重点实验室省部共建国家重点实验室培育基地青岛眼科医院

Affiliation of the Leader:

Qingdao Eye Hospital, Shandong Eye Institute, Shandong First Medical University & Shandong Academy of Medical Science

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

青眼伦审(快)[2021]18号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

青岛眼科医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Qingdao Eye Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2022-12-09 00:00:00

伦理委员会联系人:

刘小溪

Contact Name of the ethic committee:

Xiaoxi Liu

伦理委员会联系地址:

山东省青岛市市南区燕儿岛路5号

Contact Address of the ethic committee:

5 Yan'erdao Road, Shinan District, Qingdao, Shandong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山东第一医科大学(山东省医学科学院)山东省眼科研究所 山东省眼科学重点实验室省部共建国家重点实验室培育基地 青岛眼科医院

Primary sponsor:

Qingdao Eye Hospital, Shandong Eye Institute, Shandong First Medical University & Shandong Academy of Medical Science

研究实施负责(组长)单位地址:

山东省青岛市市南区燕儿岛路5号

Primary sponsor's address:

5 Yan'erdao Road, Shinan District, Qingdao, Shandong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

青岛

Country:

China

Province:

Shandong

City:

Qingdao

单位(医院):

青岛眼科医院

具体地址:

市南区燕儿岛路5号

Institution
hospital:

Qingdao Eye Hospital

Address:

5 Yan'erdao Road, Shinan District

经费或物资来源:

青岛眼科医院 开放课题

Source(s) of funding:

Open project of Qingdao Eye Hospital

Target disease:

diabetes

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

病例研究 

Study design:

Case study 

研究目的:

利用共聚焦显微镜观察2型糖尿病患者睑板腺形态变化与角膜神经变化,分析睑板腺功能障碍与角膜神经退行的相关性,为临床诊断和治疗提供理论依据  

Objectives of Study:

Confocal microscopy was used to observe the morphological changes of Meibomian gland and the changes of corneal nerve in type 2 diabetic patients, and then to analyze the correlation between them, so as to provide theoretical basis for clinical diagnosis and treatment

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 临床诊断2型糖尿病 2. 年龄>18岁 3. 角膜透明 4. 共焦显微镜显示角膜神经密度下降 5. 角膜敏感性有或无降低

Inclusion criteria

1. Clinical diagnosis of type 2 diabetes 2. Age > 18. 3.clear cornea 4. confocal microscopy showed a decrease in corneal nerve density of 5. Decreased corneal sensitivity with or without reduction

排除标准:

1. 合并角膜病变2.合并青光眼且眼压控制欠佳3.长期佩戴角膜接触镜4.角膜外伤5角膜屈光手术史6.长期使用滴眼液和眼膏7.自身免疫性疾病8.既往颅脑神经损伤术后

Exclusion criteria:

1. Complications of corneal disease (bacterial, Fungal, stromal scar, or corneal transplant)2. Complicated with Glaucoma and poor intraocular pressure control. 3. Wear contact lenses for long periods of time. 4. History of ocular trauma 5. History of corneal refractive surgery 6. Long-term use of eye drops or ointment 7. History of autoimmune diseases (such as Sj?grens syndrome, Rheumatoid Arthritis, ankylosing spondylitis, etc.)8. Clinical diagnosis of Diabetes 9. After previous surgery for cranial nerve injury

研究实施时间:

Study execute time:

From 2023-04-01 00:00:00 To 2025-04-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-04-01 00:00:00 To 2024-07-01 00:00:00  

干预措施:

Interventions:

组别:

糖尿病组

样本量:

40

Group:

Diabetes group

Sample size:

干预措施:

干预措施代码:

Intervention:

N/A

Intervention code:

组别:

正常对照组

样本量:

20

Group:

Normal control group

Sample size:

干预措施:

干预措施代码:

Intervention:

N/A

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

青岛 

Country:

China 

Province:

Shandong 

City:

Qingdao 

单位(医院):

青岛眼科医院 

单位级别:

三级 

Institution
hospital:

Qingdao Eye Hospital

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

角膜神经纤维

指标类型:

主要指标

Outcome:

Corneal neuromorphism

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

角膜上皮缺损的程度

指标类型:

主要指标

Outcome:

Degree of corneal epithelial defect

Type:

Primary indicator

测量时间点:

测量方法:

角膜荧光色钠染色

Measure time point of outcome:

Measure method:

Sodium fluorescein staining of cornea

指标中文名:

角膜敏感性

指标类型:

主要指标

Outcome:

Corneal sensitivity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

泪膜破裂时间

指标类型:

主要指标

Outcome:

Tear break-up time, TBUT

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

泪液分泌试验

指标类型:

主要指标

Outcome:

Schirmer I test

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

睑板腺腺泡和树突细胞

指标类型:

主要指标

Outcome:

Meibomian gland acini&dendritic cells

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2024.12.26 临床试验公共管理平台ResMan(www.medresman.org.cn)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

2024.12.26 ResMan, a public management platform for clinical trials (www.medresman.org.cn)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

一、病历记录表格,包括患者入院期间及门诊复诊所有临床医学资料 二、电子采集和管理系统:青岛眼科医院住院及门诊医师系统记录以及临床资料数据库

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

1. case record form, including clinical medical data during the patient’s admission period and outpatient clinic 2. Electronic collection and management system: inpatient and outpatient system records and clinical data database of Qingdao Eye Hospital

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-03-10 15:04:21